Clinically meaningful Imaging upgrade by #AlinaKüper: CAIX PET/CT detected 98% of regions vs 40% by CT; changed management in 7 pts; uptake time x up to 1.0. High SUV hints at 177Lu-CAIX theranostics. #ESMO25 #RCC @myESMO @Annals_Oncology @OncLive @OncoAlert

Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science

Our very own @MayoCancerCare Dr. Jacob Orme presents data on plasma exchange to remove soluble PD-L1 followed by ICI in patients with ICI-refractory melanoma. ORR 61%, often durable. #ESMO25

I love this blog post from my patient Haley Crider. She has become a tireless supporter of other cancer patients through her involvement in our local AYA program. It’s always helpful for me to read about the patient’s perspective on their journey.

TGen and City of Hope Cancer Center Phoenix had the privilege to partner with Matriarch Mixer last week for their September Indigenous Wellness Summit. Speakers shared about the importance of: ☝️ Prioritizing your health, 🧬 Understanding your family history and genetic makeup &

Great work from our lead long cancer med onc at City of Hop Arizona.

Congrats to @IrbazRiaz et al. on this excellent review of AI across the cancer care continuum, clear, timely, and very well written. A must-read for oncology and digital health. @JournalCancer @RamalingamMD @OncoAlert @MayoClinic @VUMChealth https://t.co/YBoda9YT4C

Who's the best candidate for Lutetium therapy? PSMA PET result matters, but 👉CT/DNA, NGS, and histology also do. Excellent talks by #MikeMorris & @sartor_oliver at #2025USPCCC Highlighting data by Eugene Kwon & @AzadOncology in @NatureMedicine👇@urotoday @PCFnews @OncoAlert

Just started👉2025 United States #ProstateCancer Consensus Conference (USPCCC) 👉with @AlanBryce9 ‘s introductory remarks. @philkuo @cityofhope debating for PSMA PET for treatment selection. Caveat👉 Medical conditions with false positive PSMA PET lesions 👇@urotoday @PCFnews

A new model for mCRPC that adds ctDNA-based genomic alterations to clinical data improves overall survival prediction by ~30%. AR, PTEN, TP53, MYC among key drivers. A step closer to precision trials. #ProstateCancer #Oncology @mishabeltran @EAntonarakis @MattGalsky

BMS-986365: a first-in-class dual AR degrader + antagonist -Potent vs wildtype & mutant AR -Superior to enzalutamide in preclinical models -PSA ↘️ in post-ARPI mCRPC patients @CCR_AACR @OncoAlert @APCCC_Lugano @OncBrothers #prostatecancer https://t.co/ruHkS9eJAi

I'm pleased to launch a new series, "Science Matters." We’ll explore why science matters, and which scientific 'matters' are key to translating cancer breakthroughs into better care for patients everywhere. I hope you enjoy the first installment!

Great data from @Ecastromarcos. It makes the point that pathogenic BRCA mutations are both predictive and prognostic in metastatic prostate cancer.

@DrYukselUrun @ASCO @OncoAlert @neerajaiims @CParkMD @TheLancet @APCCC_Lugano @Larvol @AzadOncology @yekeduz_emre @montypal @shilpaonc @VivekSubbiah @DrAndreFay @SoaresAndrey @Silke_Gillessen @dmukherji @SuyogCancer I worry that the majority of that benefit is being driven by BRCA and PLAB2. Is this going to be your 1L for all HRRm? @neerajaiims @DrRanaMcKay @dr_yakupergun PARPi have a good amount of side effects with very little benefit with certain HRR deficiencies. Love this slide by

Thank you for sharing your story and being such a relentless patient advocate @CEgglesfield, and that you for your support of @cityofhope in Arizona. And thank you to @people for covering the story.

Thanks to @montypal for hosting. And thanks to @Waltstadler5 for his no nonsense insights. I've been learning from him for many years. It's a pleasure to push the cutting edge of cancer care with colleagues like this.

A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but also enhances sensitivity to hormonal therapy. Congrats to PCF-funded Mayuko Kanayama 👏 @neerajaiims @PCFnews @urotoday @EdEsplin https://t.co/j2EzocJlys

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study out on JCO https://t.co/ziHQywB99i In this Phase 1 trial, pasritamig—a novel bispecific antibody targeting KLK2 on